What does it mean to be a Fierce 15 biotech in 2026? With this year’s list unveiled, the Fierce Biotech team gets together to discuss what the winners tell us about the state of the sector.
In this week’s episode of "The Top Line," the Fierce Biotech editorial team reflects on the process of distilling more than 150 high-quality entries into the final Fierce 15 list. The team discusses how the ambitions of these companies are higher than ever and looks back on some of its conversations with the winners, covering everything from cutting-edge antibody research and novel fertility treatments to innovative ways to source radioisotopes.
To learn more about the topics in this episode:
- Introducing Fierce Biotech's 2026 Fierce 15
- Regeneron backs $75M series A for antibody upstart Infinimmune
- Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey
- Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapy
- Fierce Biotech at London Life Sciences Week: Learn more and register
- Learn more about the Fierce Vanguard Awards Gala